Guardant Health Inc (NASDAQ:GH) Director Stanley J. Meresman sold 10,000 shares of the stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $76.36, for a total value of $763,600.00.
Shares of GH stock traded up $1.00 on Friday, reaching $61.56. The stock had a trading volume of 719,714 shares, compared to its average volume of 1,665,044. Guardant Health Inc has a 1 year low of $31.01 and a 1 year high of $112.21. The company has a 50 day simple moving average of $76.07 and a 200 day simple moving average of $81.08. The stock has a market cap of $5.72 billion and a P/E ratio of -21.99.
Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.21. The business had revenue of $53.98 million for the quarter, compared to analysts’ expectations of $35.97 million. Guardant Health had a negative return on equity of 22.93% and a negative net margin of 60.08%. The business’s quarterly revenue was up 178.5% on a year-over-year basis. During the same period last year, the firm earned ($1.75) earnings per share. As a group, sell-side analysts predict that Guardant Health Inc will post -1.27 EPS for the current year.
A number of research analysts have commented on the company. Zacks Investment Research raised Guardant Health from a “hold” rating to a “buy” rating and set a $68.00 price target for the company in a research report on Wednesday. Cowen set a $110.00 target price on Guardant Health and gave the stock a “buy” rating in a research report on Wednesday, August 7th. JPMorgan Chase & Co. upped their price target on Guardant Health from $90.00 to $135.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $125.00 target price (up from $96.00) on shares of Guardant Health in a research note on Wednesday, August 7th. Seven analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus price target of $104.40.
Large investors have recently bought and sold shares of the business. Advantage Investment Management LLC increased its holdings in shares of Guardant Health by 200.0% in the second quarter. Advantage Investment Management LLC now owns 450 shares of the company’s stock worth $39,000 after purchasing an additional 300 shares during the last quarter. HM Payson & Co. purchased a new position in Guardant Health in the second quarter worth about $43,000. Oppenheimer Asset Management Inc. purchased a new position in Guardant Health in the second quarter worth about $62,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Guardant Health in the second quarter worth about $76,000. Finally, FNY Investment Advisers LLC grew its position in Guardant Health by 7,816.7% in the second quarter. FNY Investment Advisers LLC now owns 950 shares of the company’s stock worth $82,000 after acquiring an additional 938 shares in the last quarter. 81.40% of the stock is currently owned by institutional investors and hedge funds.
About Guardant Health
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.
See Also: What factors cause inflation to rise?
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.